

PRODUCT INFORMATION



ICI 192605

Item No. 10135

CAS Registry No.: 117621-64-4
Formal Name: (4Z)-rel-6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid

MF: C₂₂H₂₃ClO₅

FW: 402.9


Purity: ≥95%

UV/Vis.: λ_{max}: 274 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

ICI 192605 is supplied as a crystalline solid. A stock solution may be made by dissolving the ICI 192605 in the solvent of choice. ICI 192605 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ICI 192605 in ethanol is approximately 25 mg/ml and approximately 30 mg/ml in DMSO and DMF.

ICI 192605 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ICI 192605 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ICI 192605 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

ICI 192605 is a potent antagonist of the thromboxane A₂ receptor (TP) that blocks contraction of isolated guinea pig trachea induced by U-46619 (Item No. 16450; K_d = 0.398 nM).^{1,2} It is used to study the role of TP signaling in tissues and animals.³⁻⁶

References

1. Brewster, A.G., Brown, G.R., Foubister, A.J., *et al.* The synthesis of a novel thromboxane receptor antagonist 4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid ICI 192605. *Prostaglandins* **36(2)**, 173-178 (1988).
2. Dubuffet, T., Muller, O., Simonet, S.S., *et al.* Synthesis of new 3,4-disubstituted pyrrolidines as thromboxane A₂/prostaglandin H₂ (TP) receptor antagonists. *Bioorg. Med. Chem. Lett.* **6(4)**, 349-352 (1996).
3. Hausermann, L. and St-Louis, J. Thromboxane and isoprostane share the same prostanoid receptors to increase human placental tone. *Placenta* **32(12)**, 941-948 (2011).
4. Hewitt, M.M., Adams, G., Jr., Mazzone, S.B., *et al.* Pharmacology of bradykinin-evoked coughing in guinea pigs. *J. Pharmacol. Exp. Ther.* **357(3)**, 620-628 (2016).
5. Janssen, L.J. and Tazzeo, T. Involvement of TP and EP₃ receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. *J. Pharmacol. Exp. Ther.* **301(3)**, 1060-1066 (2002).
6. Pettipher, R., Hansel, T.T., and Armer, R. Antagonism of the prostaglandin D₂ receptors DP₁ and CRTH2 as an approach to treat allergic diseases. *Nat. Rev. Drug Discov.* **6**, 313-325 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/20/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM